Exakte Wirkstoffkennungen und zitierbare Passagen zu Wechselwirkungen, Gegenanzeigen und Nebenwirkungen.
Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
• Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
• Active clinically significant bleeding.
• Hepatic disease associated with coagulopathy and clinically relevant bleeding risk (see
section 5.2).
• Lesion or condition if considered a significant risk factor for major bleeding. This may include
current or recent gastrointestinal ulceration, presence of malignant neoplasms at high risk of
bleeding, recent brain or spinal injury, recent brain, spinal or ophthalmic surgery, recent
intracranial haemorrhage, known or suspected oesophageal varices, arteriovenous
malformations, vascular aneurysms or major intraspinal or intracerebral vascular
abnormalities.
• Concomitant treatment with any other anticoagulant agent e.g., unfractionated heparin (UFH),
low molecular weight heparins (enoxaparin, dalteparin, etc.), heparin derivatives
(fondaparinux, etc.), oral anticoagulants (warfarin, rivaroxaban, dabigatran etexilate etc.)
except under specific circumstances of switching anticoagulant therapy (see section 4.2), when
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
• Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
• Active clinically significant bleeding.
• Hepatic disease associated with coagulopathy and clinically relevant bleeding risk (see
section 5.2).
• Lesion or condition if considered a significant risk factor for major bleeding. This may include
current or recent gastrointestinal ulceration, presence of malignant neoplasms at high risk of
bleeding, recent brain or spinal injury, recent brain, spinal or ophthalmic surgery, recent
intracranial haemorrhage, known or suspected oesophageal varices, arteriovenous
malformations, vascular aneurysms or major intraspinal or intracerebral vascular
abnormalities.
• Concomitant treatment with any other anticoagulant agent e.g., unfractionated heparin (UFH),
low molecular weight heparins (enoxaparin, dalteparin, etc.), heparin derivatives
(fondaparinux, etc.), oral anticoagulants (warfarin, rivaroxaban, dabigatran etexilate, etc.)
except under specific circumstances of switching anticoagulant therapy (see section 4.2), when
UFH is given at doses necessary to maintain an open central venous or arterial catheter or
when UFH is given during catheter ablation for atrial fibrillation (see sections 4.4 and 4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Version 2026-07-27T13:45:00Z · SHA-256 d61ca619dbc3cc41b936fd00150a7483792c8b53e4c986c4c86af1cceab6e2ab · Passage 374842bdd6ce37e26c86500c4eae2c73d5e2b44de65090de8528c323aa87b47a · Zeichen 0–1413 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.